Live Breaking News & Updates on Iopharmaceutical company

Stay informed with the latest breaking news from Iopharmaceutical company on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Iopharmaceutical company and stay connected to the pulse of your community

Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA)

Director Amit Munshi has recently increased his stake in Zura Bio Ltd (NASDAQ:ZURA) by purchasing 159,744 shares of the company, as per the SEC Filing dated 2024-04-22.

Zura-bio-ltd , Eriod-zura-bio-ltd , Iopharmaceutical-company , Mit-munshi ,

Director Gregory Bailey Acquires 48,780 Shares of Biohaven Ltd (BHVN)

Director Gregory Bailey has recently increased his stake in Biohaven Ltd (NYSE:BHVN) by purchasing 48,780 shares of the company's stock, according to a SEC Filing dated 2024-04-22.

Biohaven-ltd , Regory-bailey , Iopharmaceutical-company , Nsider-transaction ,

Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.

Agios-pharmaceuticals-inc , Jacqualyn-fouse , Iopharmaceutical-company , Gios-pharmaceuticals , Nsider-transaction , Nsider-transactions , Nsider-activity ,

ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.

Pharmaceuticals-inc , Gurufocus-value , Acadia-pharmaceuticals , Tephen-davis , Iopharmaceutical-company , Entral-nervous-system-disorders ,

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team with the appointment of industry veteran as President of Research & DevelopmentDr. Shah’s joins Oculis from Iveric Bio with extensive experience in drug development, regulatory affairs and ophthalmology, with over a dozen successful market approvals, which will be key as Oculis initiates preparations

Boston , Massachusetts , United-states , Switzerland , France , Sylvia-cheung , Corey-davis , Snehal-shah , Roche-genentech , Iveric-bio , Drug-administration , Research-development

What Makes Insmed (INSM) a Lucrative Investment?

ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the benchmark in the quarter. The small-cap growth universe revealed a stark dichotomy despite the positive performance of the benchmark Russell 2000 Growth Index, which […]

Insmed-incorporated , Popular-stocks-among-hedge , Learbridge-investments , Iopharmaceutical-company , Nvestment-management-company ,

Samsung Bioepis Initiates Phase 3 Clinical Trial for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)

INCHEON, Korea, April 05, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company's proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda in patients with metastatic non-squamous non-small cell lung cancer. Patients will b

United-states , Turkey , Mexico , Georgia , India , Thailand , Malaysia , Spain , Germany , Japan , Serbia , Philippines

CEO Bhatnagar Anish Sells 18,980 Shares of Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Soleno-therapeutics-inc , Iopharmaceutical-company , Hatnagar-anish , Nsider-trading , Nsider-transactions ,

Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares

Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of the company on April 1, 2024, according to a recent SEC Filing.

Madrigal-pharmaceuticals-inc , Iopharmaceutical-company , Ichard-levy , Nsider-transactions ,

Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focusing on the development and commercialization of novel therapies that address unmet needs in the treatment of liver and cardiovascular diseases, has reported a significant insider sell according to the latest SEC filings.

Madrigal-pharmaceuticals-inc , Pharmaceuticals-inc , Kenneth-bate , Iopharmaceutical-company , Nsider-transactions , Ardiovascular-diseases , Nsider-transaction ,